BACKGROUND: In treatment-naive, human immunodeficiency virus (HIV)-infected persons, combination antiretroviral therapy (cART) incorporating raltegravir (RAL) is highly effective for virologic suppression, but characteristics of immunologic recovery have not been described. METHODS: We performed a 48-week substudy of 15 patients, median age 40 years, within a phase 2 randomized trial of RAL-cARTin treatment-naive patients with chronic HIV infection. RESULTS:Plasma viral load decreased from 5.2 ± 5.3 log10 HIV RNA copies/mL to 2.2 ± 2.4 log10 copies/mL at week 4, reaching <50 copies/mL at week 8 in 13 of 15 patients. Total CD4 T cells increased at week 4, as did central memory CD4 T cells in association with reduction of the immune activation markers HLA-DR and CD38 and immune exhaustion marker PD1 in CD4 and CD8 T cells. Naive CD4 T cells increased at week 24 with appearance of HIV gag-specific interleukin 2, interferon-γ, and CD107a responses in CD4 and CD8 T cells at week 48. Plasma lipopolysaccharide and solubleCD14 decreased, but at week 48 were elevated as compared to healthy volunteers. Altogether, the week 48 immune profile was more favorable in patients taking RAL-cART than in patients treated with non-RAL-cART. CONCLUSIONS: RAL in first-line treatment regimens results in rapid immune reconstitution with residual low-level microbial translocation.
RCT Entities:
BACKGROUND: In treatment-naive, human immunodeficiency virus (HIV)-infectedpersons, combination antiretroviral therapy (cART) incorporating raltegravir (RAL) is highly effective for virologic suppression, but characteristics of immunologic recovery have not been described. METHODS: We performed a 48-week substudy of 15 patients, median age 40 years, within a phase 2 randomized trial of RAL-cART in treatment-naive patients with chronic HIV infection. RESULTS: Plasma viral load decreased from 5.2 ± 5.3 log10 HIV RNA copies/mL to 2.2 ± 2.4 log10 copies/mL at week 4, reaching <50 copies/mL at week 8 in 13 of 15 patients. Total CD4 T cells increased at week 4, as did central memory CD4 T cells in association with reduction of the immune activation markers HLA-DR and CD38 and immune exhaustion marker PD1 in CD4 and CD8 T cells. Naive CD4 T cells increased at week 24 with appearance of HIV gag-specific interleukin 2, interferon-γ, and CD107a responses in CD4 and CD8 T cells at week 48. Plasma lipopolysaccharide and soluble CD14 decreased, but at week 48 were elevated as compared to healthy volunteers. Altogether, the week 48 immune profile was more favorable in patients taking RAL-cART than in patients treated with non-RAL-cART. CONCLUSIONS:RAL in first-line treatment regimens results in rapid immune reconstitution with residual low-level microbial translocation.
Authors: Martin Montes; Cesar Sanchez; Dorothy E Lewis; Edward A Graviss; Carlos Seas; Eduardo Gotuzzo; A Clinton White Journal: J Infect Dis Date: 2010-12-21 Impact factor: 5.226
Authors: Netanya G Sandler; Handan Wand; Annelys Roque; Matthew Law; Martha C Nason; Daniel E Nixon; Court Pedersen; Kiat Ruxrungtham; Sharon R Lewin; Sean Emery; James D Neaton; Jason M Brenchley; Steven G Deeks; Irini Sereti; Daniel C Douek Journal: J Infect Dis Date: 2011-01-20 Impact factor: 5.226
Authors: Maria J Buzón; Marta Massanella; Josep M Llibre; Anna Esteve; Viktor Dahl; Maria C Puertas; Josep M Gatell; Pere Domingo; Roger Paredes; Mark Sharkey; Sarah Palmer; Mario Stevenson; Bonaventura Clotet; Julià Blanco; Javier Martinez-Picado Journal: Nat Med Date: 2010-03-14 Impact factor: 53.440
Authors: Martin Markowitz; Bach-Yen Nguyen; Eduardo Gotuzzo; Fernando Mendo; Winai Ratanasuwan; Colin Kovacs; Guillermo Prada; Javier O Morales-Ramirez; Clyde S Crumpacker; Robin D Isaacs; Lucinda R Gilde; Hong Wan; Michael D Miller; Larissa A Wenning; Hedy Teppler Journal: J Acquir Immune Defic Syndr Date: 2007-10-01 Impact factor: 3.731
Authors: N R Klatt; J D Estes; X Sun; A M Ortiz; J S Barber; L D Harris; B Cervasi; L K Yokomizo; L Pan; C L Vinton; B Tabb; L A Canary; Q Dang; V M Hirsch; G Alter; Y Belkaid; J D Lifson; G Silvestri; J D Milner; M Paiardini; E K Haddad; J M Brenchley Journal: Mucosal Immunol Date: 2012-05-30 Impact factor: 7.313
Authors: Matthieu Perreau; Anne-Laure Savoye; Elisa De Crignis; Jean-Marc Corpataux; Rafael Cubas; Elias K Haddad; Laurence De Leval; Cecilia Graziosi; Giuseppe Pantaleo Journal: J Exp Med Date: 2012-12-17 Impact factor: 14.307
Authors: Suresh Pallikkuth; Mark Sharkey; Dunja Z Babic; Sachin Gupta; Geoffrey W Stone; Margaret A Fischl; Mario Stevenson; Savita Pahwa Journal: J Virol Date: 2015-12-16 Impact factor: 5.103
Authors: María J Villanueva-Millán; Patricia Pérez-Matute; Emma Recio-Fernández; José M Lezana Rosales; José A Oteo Journal: J Int AIDS Soc Date: 2017-03-09 Impact factor: 5.396
Authors: Jose F Camargo; Suresh Pallikkuth; Ilona Moroz; Yoichiro Natori; Maria L Alcaide; Allan Rodriguez; Giselle Guerra; George W Burke; Savita Pahwa Journal: Kidney Int Rep Date: 2019-08-19